We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Droplet PCR System Identifies Fetal Genetic Data

By HospiMedica International staff writers
Posted on 24 Nov 2015
A new study describes a simple, accurate, and low risk blood test that can detect fetal blood group, sex, and genetic conditions from a maternal blood sample. More...


Developed by researchers at Plymouth University (United Kingdom), the new noninvasive fetal Rh blood group and D antigen (RhD) genotyping test can help prevent unnecessary administration of prophylactic anti-D to women carrying RHD-negative fetuses. The blood sample can be taken from the mother when she has her first appointment with a general practitioner (GP) or midwife at the early stages of pregnancy, negating the need for multiple appointments and making best use of healthcare resources.

A study to validate the new test, which is based on a novel droplet digital polymerase chain reaction (ddPCR) platform to detect the cell-free fetal DNA (cffDNA) fraction, found that dPCR demonstrated 100% sensitivity for both fetal sex determination and RHD genotyping. The test can also be carried out on mothers at risk of X-linked genetic recessive diseases, including hemophilia and Duchenne muscular dystrophy, as well as mothers at risk of hemolytic disease of the newborn. The study was published in the November 2015 issue of Clinical Chemistry.

“Use of dPCR for identification of fetal specific markers can reduce the occurrence of false-negative and inconclusive results, particularly when samples express high levels of background maternal cell-free DNA,” concluded senior author Prof. Neil Avent, PhD, of the Plymouth University School of Biomedical and Healthcare Sciences. “The technique represents a comparatively low-risk method for the early identification of a number of conditions, which in turn will aid earlier diagnosis and possible therapies to the potential benefit of both mother and child.”

ddPCR is based on water-oil emulsion droplet technology; a sample is fractionated into 20,000 nanoliter-sized droplets, serving essentially the same function as individual test tubes or wells in a PCR plate, albeit in a much smaller format. The massive sample partitioning is a key aspect of the ddPCR technology, enabling high-throughput digital PCR in a manner that uses lower sample and reagent volumes and reduces overall cost, while still maintaining the sensitivity and precision of current digital PCR systems.

Related Links:

Plymouth University



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Leg Wraps
Leg Wraps
New
Mobile X-Ray Machine
MARS 15 / 30
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The engine-free, nonlinear, flexible, micro-robotic platform leverages AI to optimize GBM treatment (Photo courtesy of Symphony Robotics)

First-Ever MRI-Steerable Micro-Robotics to Revolutionize Glioblastoma Treatment

Glioblastoma Multiforme (GBM) is one of the most aggressive and difficult-to-treat brain cancers. Traditional surgical procedures, such as craniotomies, involve significant invasiveness, requiring large... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.